InVision Medical Technology vs RapidSOS

The only genuine overlap is the phrase "AI in healthcare-adjacent settings," which is not a comparison point. InVision Medical Technology's function set is clinical: automated LVEF from standard echo DICOM, amyloidosis detection from A4C and PLAX views, multi-valve analysis, and DICOM-native post-processing with no new hardware. Its vendor-neutral design runs across GE, Philips, Siemens, Canon, handheld POCUS, and slots into PACS, CVIS, and Epic EHR. Validation is regulatory and academic: FDA 510(k) for Precision LVEF and Precision Cardiac Amyloid, Breakthrough Device designation, TAP enrollment, and a randomized controlled trial in Nature (2023). The June 2026 Precision Reporting launch extends this with the EchoPrime foundation model and EchoNet-Measurements to auto-generate structured reports with 18 measurements and draft wording. RapidSOS's feature set is operational emergency response: an AI Assistant for call takers, Harmony transcription/translation across calls, text, and video, Live Video Streaming from callers, Drone-as-First-Responder launch, Air Ambulance Dispatch, non-emergency call deflection, and pre-call telematics/hazmat/sensor context. Where InVision's output is a measurement or a draft report, RapidSOS's output is a dispatch decision and responder situational awareness. Different inputs, different outputs, different operators.

Both list "contact" pricing, but the cost structures share nothing else. InVision Medical Technology has an explicit reimbursement spine: CPT Category III code 0932T (effective January 1, 2025) for AI-assisted echo evaluation in heart failure patients, and as of October 1, 2026, a Medicare New Technology Add-on Payment of up to $2,275 per eligible inpatient stay for Precision Cardiac Amyloid. Those are revenue-side numbers a health system uses to underwrite the contract — the software license itself is negotiated per site, typically against an echo lab's study volume. RapidSOS pricing is a network/contract model for 911 ECCs, state safety networks, and enterprise partners whose incidents reach 911; there is no published per-call or per-seat rate, and no reimbursement code involved. Cost justification for RapidSOS comes from call-handling efficiency, non-emergency deflection, and pre-call data that shortens dispatch time — operational ROI, not billing codes. In short: InVision buyers model CPT 0932T and NTAP dollars against their echo volume; RapidSOS buyers model ECC throughput and enterprise incident-response value against a mission-critical platform contract. There is no price point at which these two quotes are compared.